PD-L1/2: ПРОГНОСТИЧНЕ ЗНАЧЕННЯ В ОНКОЛОГІЇ
Ключові слова:
солідні злоякісні пухлини, лімфопроліферативні захворювання, імунні контрольні точки, PD-1, PD-L1/2, прогностичні фактори, програмована загибель клітини, Т-лімфоцити.Анотація
Мета огляду: аналіз сучасних відомостей щодо прогностичного значення
експресії білків PD-L1/2 (program death ligand) на клітинах злоякісних новоутворень (ЗН) різного гістогенезу та локалізації. Більшість досліджень
свідчить про несприятливу прогностичну роль експресії PD-L1/2 у клітинах ЗН епітеліального походження, меланомах, саркомах та при онкогематологічних захворюваннях (хоча останні вивчені в цьому плані меншою
мірою). Це ілюструється гіршими показниками виживаності пацієнтів,
особливостями гістоструктури пухлини, розповсюдженими стадіями, що
виявляються при гіперекспресії цих молекул. Продовження досліджень цього маркера може сприяти подальшому прогресу у розумінні патогенезу ЗН
та прискорити розробку інноваційних терапевтичних опцій.
Посилання
Dolan DE, Gupta S. PD-1 pathway inhibitors: changing
the landscape of cancer immunotherapy. Cancer Contro 2014;
(3): 231–7.
Riley JL. PD-1 signaling in primary T cells. J Immunol rev
; 229: 114–25.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression
of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11 (11): 3887–95.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and
its ligands in tolerance and immunity. Annu Rev Immunol 2008;
: 677–704.
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5 (12): 1365–69.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the
PD-1 immunoinhibitory receptor by a novel B7 family member
leads to negative regulation of lymphocyte activation. J Exp Med
; 192 (7): 1027–34.
Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J
Exp Med 2001; 193 (7): 839–46.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol
; 2 (3): 261–68.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated
B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (8): 793–800.
Topalian SL, Sznol M, Mcdermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32
(10): 1020–30.
Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to
Hodgkin lymphoma. J Exp Med 2003; 198 (6): 851–62.
Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1
on tumor cells in the escape from host immune system and tumor
immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA
; 99 (19): 12293–97.
Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111 (7): 3635–43.
Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/
B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr
Opin Immunol 2012; 24 (2): 207–12.
Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PDL1, IDO, and T(regs) in the melanoma tumor microenvironment is
driven by CD8(+) T cells. Sci Transl Med 2013; 5 (200): 200ra116.
Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13 (1): 84–8.
Gao Q, Wang X-Y, Qiu S-J, et al. Overexpression of PD-L1
significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer
Res 2009; 15 (3): 971–9.
Guo W, Wang P, Li N, et al. Prognostic value of PD-L1 in
esophageal squamous cell carcinoma: a meta-analysis. Oncotarget 2017; 9 (17): 13920–33.
Zhuan-Sun Y, Huang F, Feng M, et al. Prognostic value of
PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis. Onco Targets Ther 2017; 10: 5005–12.
Zhang M, Dong Y, Liu H, et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric
cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep
; 6: 37933.
Yang C-Y, Lin M-W, Chang Y-L, et al. Programmed cell
death-ligand 1 expression in surgically resected stage I pulmonary
adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014; 50 (7): 1361–9.
Jong-Mu Sun, Wei Zhou, Yoon-La Choi. PD-L1 expression and survival in patients with non-small cell lung cancer in Korea. J Clin Oncol 2014; 32 (5): 8066.
Sun JM, Zhou W, Choi YL, et al. Prognostic significance of
PD-L1 in patients with non-small cell lung cancer: a large cohort study
of surgically resected cases. J Thorac Oncol 2016; 11 (7): 1003–11.
Hidefumi S, Tsutomu T, Katsuhiro O, et al. PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small
cell lung cancer. Mol Clin Oncol 2014; 2 (6): 1035–42.
Hino R. Tumor cell expression of programmed cell death-1
ligand 1 is a prognostic factor for malignant melanoma. Cancer
; 116 (7): 1757–66.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity,
and immune correlates of anti-PD-1 antibody in cancer. N Engl J
Med 2012; 366 (26): 2443–54.
Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with
nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol
; 31 (suppl): 3016.
Iacovelli R, Nolè F, Verri E, et al. Prognostic role of PD-L1
expression in renal cell carcinoma. A systematic review and metaanalysis. Target Oncol 2016; 11 (2): 143–8.
Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in
breast cancer: a meta-analysis. BMC Cancer 2017; 17 (1): 690.
Müller T, Braun M, Dietrich D, et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget 2017; 8 (32): 52889–900.
Aghajani M, Graham S, McCafferty C, et al. The clinicopathological and prognostic significance of programmed cell
death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis. Thyroid 2018; 28 (3): 349–61.
Zhang Y, Kang S, Shen J, et al. Prognostic significance of
programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1). Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 2015; 94 (6): e515.
Zhu Z, Jin Z, Zhang M, et al. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Oncotarget
; 8 (35): 59570–80.
Rosenwald A, Wright G, Leroy K. Molecular diagnosis of
primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. JEM 2003; 198 (6): 851.
Kim C, Kim EK, Jung H, et al. Prognostic implications of
PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 2016; 16: 434.
Liu YX, Wang XS, Wang YF, et al. Prognostic significance
of PD-L1 expression in patients with gastric cancer in East Asia:
a meta-analysis. Onco Targets Ther 2016; 9: 2649–54.
Dai C, Wang M, Lu J, et al. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer:
a meta-analysis. Onco Targets Ther 2017; 10: 3625–34.
Li J, Wang P, Xu Y. Prognostic value of programmed cell
death ligand 1 expression in patients with head and neck cancer:
A systematic review and meta-analysis. PLoS One 2017; 12 (6):
e0179536.
Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in
solid tumor: An updated meta-analysis. Medicine (Baltimore)
; 96 (18): e6369.
Bellmunt J, Mullane SA, Werner L, et al. Association of
PD-L1 expression on tumor-infiltrating mononuclear cells and
overall survival in patients with urothelial carcinoma. Ann Oncol
; 26 (4): 812–7.
Vital D, Holzmann D, Huber GF, et al. PD-L1 is a positive
prognostic factor in squamous cell carcinoma of the nasal vestibule. Rhinology 2018. doi: 10.4193/Rhin17.215.
Boussiotis VA. Cell-specific PD-L1 expression in DLBCL.
Blood 2015; 126 (19): 2171–2.
Kiyasu J, Miyoshi H, Hirata A, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015;
(19): 2193–201.
Miyoshi H, Kiyasu J, Kato T, et al. PD-L1 expression on
neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood 2016; 128
(10): 1374–81.
Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression
in Hodgkin and B-cell lymphomas. Hum Pathol 2016; 54: 17–24.
Svergun N, Khranovska N, Kriachok I, et al. The role of
microenvironment expression of PD-1 ligands and chemokines
in clinical outcome of hodgkin’s lymphoma. Ann Oncol 2014; 25
(4): iv329.
